Grok found it.....The study referenced in the X post is a 2022 retrospective observational clinical study titled "Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants", authored by Honglin Chen and colleagues. It was published in the open-access journal Frontiers in Cardiovascular Medicine (volume 9, article 964977). You can read the full text here: https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.964977/full (or via PubMed: https://pubmed.ncbi.nlm.nih.gov/36072877/). Key Details Location/Origin: The study was conducted in China. Participants were patients with hyperlipidemia and/or mild atherosclerosis who used an approved nattokinase product manufactured by Sungen Bioscience Co., Ltd. (Shantou, Guangdong Province). Data were retrospectively analyzed from records between 2016–2020. Design: Retrospective analysis of real-world data from 1,062 participants (average age ~67.5 years) taking high-dose nattokinase (primarily 10,800 FU/day) for 12 months. Note: This is distinct from an earlier 2017 Chinese study (Ren et al.) with fewer participants (~76 completing) and a lower dose, which also reported ~36% plaque reduction but is not the one cited in the post. The study reports no serious adverse effects at this dose, but it emphasizes consulting a doctor due to nattokinase's blood-thinning properties.
Grok found it.....The study referenced in the X post is a 2022 retrospective observational clinical study titled "Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants", authored by Honglin Chen and colleagues. It was published in the open-access journal Frontiers in Cardiovascular Medicine (volume 9, article 964977). You can read the full text here: https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.964977/full (or via PubMed: https://pubmed.ncbi.nlm.nih.gov/36072877/). Key Details Location/Origin: The study was conducted in China. Participants were patients with hyperlipidemia and/or mild atherosclerosis who used an approved nattokinase product manufactured by Sungen Bioscience Co., Ltd. (Shantou, Guangdong Province). Data were retrospectively analyzed from records between 2016–2020. Design: Retrospective analysis of real-world data from 1,062 participants (average age ~67.5 years) taking high-dose nattokinase (primarily 10,800 FU/day) for 12 months. Note: This is distinct from an earlier 2017 Chinese study (Ren et al.) with fewer participants (~76 completing) and a lower dose, which also reported ~36% plaque reduction but is not the one cited in the post. The study reports no serious adverse effects at this dose, but it emphasizes consulting a doctor due to nattokinase's blood-thinning properties.
Perfect! Thank you.
Yw